Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non-small cell lung cancer.
Xu Y, Yan J, Zhou C, Wu L, Wang H, Zhao J, Zhou M, Wang J, Zheng X, Zhang L, Jiang K, Zheng X, Miao Q, Wu S, Zou Z, Lian R, He Y, Chen R, Yang S, Li Y, Chen S, Lin G.
Xu Y, et al. Among authors: wang h, wang j.
Eur J Cancer. 2023 Jul;188:81-89. doi: 10.1016/j.ejca.2023.04.009. Epub 2023 Apr 20.
Eur J Cancer. 2023.
PMID: 37201385